New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case-control MISSIL study.
Letarouilly JG, Pham T, Pierache A, Acquacalda É, Banneville B, Barbarot S, Baudart P, Bauer É, Claudepierre P, Constantin A, Dernis E, Felten R, Gaudin P, Girard C, Gombert B, Goupille P, Guennoc X, Henry-Desailly I, Jullien D, Karimova E, Lanot S, Le Dantec L, Pascart T, Plastaras L, Sultan N, Truchet X, Varin S, Wendling D, Gaboriau L, Staumont-Sallé D, Peyrin-Biroulet L, Flipo RM.
Letarouilly JG, et al. Among authors: felten r.
Rheumatology (Oxford). 2022 Jul 6;61(7):2848-2855. doi: 10.1093/rheumatology/keab819.
Rheumatology (Oxford). 2022.
PMID: 34730790